Abstract

Linezolid is used to treat prosthetic joint infection after total hip arthroplasty. Here, we present a case of linezolid-induced severe neutropenia, which improved after switching to tedizolid. Grade 3 neutropenia developed 5 days after linezolid injection (1,200 mg/day) and 33 days after oral administration of the same dose. However, during the 70 days of treatment with tedizolid, grade 3 neutropenia did not occur, and C-reactive protein levels remained in the normal range. No grade ≥ 1 thrombocytopenia or bleeding event occurred during the course of tedizolid treatment. Tedizolid may be an alternative drug for patients who develop linezolid-induced neutropenia.


Author Details

Authors

• Shunsuke Kobayashi¹
• Masanori Kase²
• Masaaki Matsubara²
• Akira Kitaoka¹
• Takeo Yasu³

Departments

• ¹ Department of Pharmacy, Nissan Tamagawa Hospital, Tokyo,
• ² Department of Orthopedic Surgery, Nissan Tamagawa Hospital, Tokyo, and
• ³ Department of Medicinal Therapy Research, Pharmaceutical Education and Research Center, Meiji Pharmaceutical University, Tokyo, Japan

Address


Shunsuke Kobayashi, MSc

Department of 
Pharmacy
Nissan Tamagawa Hospital
4-8-1, Seta, Setagaya-ku, Tokyo 158-0095, Japan
Email: shunsukekobayashi0412
@gmail.com

Citation